Back to top
more

Esperion Therapeutics (ESPR)

(Delayed Data from NSDQ)

$2.21 USD

2.21
6,009,748

+0.09 (4.25%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $2.24 +0.03 (1.36%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 5.66% and 20.16%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

When Journey Medical (DERM) reports fourth-quarter 2023 results, investors will likely focus on the top and bottom-line numbers.

Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?

by Zacks Equity Research

Viatris' (VTRS) Q4 results are likely to gain from momentum in its branded and generic businesses.

Can Rising Operating Costs Affect Acadia's (ACHC) Q4 Earnings?

by Zacks Equity Research

Acadia Healthcare's (ACHC) fourth-quarter results are likely to reflect increasing patient days and admissions.

Can Higher Admissions Drive Universal Health (UHS) Q4 Earnings?

by Zacks Equity Research

Universal Health's (UHS) fourth-quarter results are likely to reflect improved performances from the Acute Care Hospital Services and Behavioral Health Care Services businesses.

Can Low Occupancy Rate Affect Select Medical (SEM) Q4 Earnings?

by Zacks Equity Research

Select Medical's (SEM) fourth-quarter results are likely to reflect growing visits in Outpatient Rehabilitation and Concentra.

Lantheus (LNTH) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Lantheus' (LNTH) fourth-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ensign Group (ENSG) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Ensign Group (ENSG) delivered earnings and revenue surprises of 0.79% and 0.54%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo

by Zacks Equity Research

Daiichi Sankyo amends its existing collaboration with Esperion (ESPR), including the resolution of a commercial dispute over milestone payments. This amendment is valued at $125 million.

FDA Updates Labels of Esperion's (ESPR) Cholesterol-Lowering Drugs

by Zacks Equity Research

The label to Esperion's (ESPR) marketed drugs Nexletol and Nexlizet have been updated to include the treatment of primary hyperlipidemia as a qualifier for existing approved populations.

Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Esperion Therapeutics (ESPR) Up 51.4% Since Last Earnings Report?

by Zacks Equity Research

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues

by Zacks Equity Research

Esperion's (ESPR) third-quarter earnings and revenues beat estimates on the back of better-than-expected collaboration revenues. The company reiterates its financial guidance for 2023.

Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 11.90% and 10.16%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Cronos Group (CRON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Esperion Therapeutics (ESPR) Down 10.6% Since Last Earnings Report?

by Zacks Equity Research

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion (ESPR) Aims to Expand Key Drug Labels for Growth

by Zacks Equity Research

Esperion's (ESPR) non-statin approved drugs uptake has continued to be the growth driver since launch. However, the company is currently facing a conflict with its partner, Daiichi Sankyo, regarding milestone payments.

Esperion (ESPR) Q2 Earnings Top, Stock Up on Strong Revenues

by Zacks Equity Research

Esperion's (ESPR) second-quarter earnings and revenues beat estimates. The stock surged 7.64% on Tuesday.

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 26.98% and 1.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Esperion (ESPR) to Expand Nilemdo and Nustendi Label in Europe

by Zacks Equity Research

Esperion (ESPR) files type II(a) variation application for expanded use of Nilemdo and Nustendi in Europe to reduce cardiovascular risk.

Why Is Esperion Therapeutics (ESPR) Down 6.9% Since Last Earnings Report?

by Zacks Equity Research

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Esperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up

by Zacks Equity Research

Esperion (ESPR) reports mixed first-quarter 2023 results, wherein earnings miss and revenues beat estimates. The stock of the company surges 5% on Tuesday. The company maintains 2023 guidance.

Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -21.54% and 15.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Stevanato Group (STVN) Q1 Earnings Lag Estimates

by Zacks Equity Research

Stevanato (STVN) delivered earnings and revenue surprises of -7.69% and 1.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?